Five Weeks Postpartum: Three Medications, a "Just Enough" Supply, and a Request for the Combined Pill

• Labetalol: transfer into milk is low and infant exposure is generally considered minimal; it is one of the antihypertensives of choice in lactation. Monitoring is proportionate to infant vulnerability - for a term 5 kg infant gaining 28 g/day, watch for unusual sleepiness, poor feeding, bradycardia or hypotonia at routine contacts. A preterm, low-birth-weight or unwell infant would justify closer observation.
• Sertraline: one of the preferred SSRIs in lactation, with low relative infant dose and a large observational evidence base; it is also the drug she is already established on. Counselling points: watch for poor feeding, irritability, excessive sleepiness or changes in stooling, which are uncommon. Do not stop a drug that is working to "protect" the infant.
• Ferrous sulfate: no concern; note that iron can darken stools and cause constipation in mother, and that infant stool changes are not attributable to it.

What matters here is the pattern, not the list: she is on three medicines and describes supply as "just enough." Antihypertensives as a class are not a recognised cause of low supply; the far more likely contributors are return-to-work anticipatory anxiety, inadequate removal if feeds are being shortened, and the untreated component of her mood disorder. Resist the temptation to blame a drug and miss the real driver.

Monitoring plan: confirm infant weight trajectory at each contact, ask specifically about feeding, alertness and stooling, and check maternal blood pressure and mood. If any new medicine is added, check the interaction and the infant-monitoring expectations at that point rather than adding a standing warning.

Frame the two competing risks first: venous thromboembolism risk is still elevated at 5 weeks postpartum (it falls substantially after the first weeks but is not back to baseline), and she has a supply she already perceives as marginal.

• Combined oestrogen-progestogen methods: not absolutely contraindicated at 5 weeks in a woman with no other VTE risk factors, but oestrogen can reduce milk volume in an already "just enough" mother, and her VTE risk is not yet fully resolved. Given her stated concern about supply, this is a poor first choice - not because it is forbidden, but because there are better fits.
• Progestin-only options - preferred: progestin-only pill (requires strict adherence, ~3-hour window, which is a real issue on shift work), etonogestrel implant (most effective, no adherence demand, no established supply effect), levonorgestrel IUD (effective, minimal systemic hormone), DMPA (convenient but may be associated with delayed return to fertility and is less reversible if side effects occur).
• Copper IUD: no hormone, no supply concern; the trade-off is heavier, more painful periods, which she should know before choosing.
• Lactational amenorrhoea method: only reliable with amenorrhoea, exclusive/frequent breastfeeding and under 6 months - and it becomes unreliable as she returns to 10-hour shifts away from the infant.

Where my role stops: I do not prescribe. I provide the comparison, flag her supply concern explicitly so the prescriber can weigh it, and ensure she is referred to the appropriate clinician or service for insertion or a prescription, with a clear follow-up so she is not left without contraception while waiting.

Answer directly: no, and the reason is risk balance rather than reassurance.

• The exposure is small and well characterised. Sertraline has one of the lowest relative infant doses among antidepressants, and the infant is 5 weeks old, term, and thriving at 28 g/day.
• The untreated-illness risk is larger. Discontinuation now, timed to a return to work in 3 weeks, concentrates several stressors at once - a documented high-risk period for relapse of perinatal anxiety and depression. Relapse carries risks to her, to the breastfeeding relationship and to infant care.
• "Feeling better" is evidence the drug is working, not evidence it is no longer needed. That distinction is worth saying out loud, because it is the belief underneath the question.
• The decision is hers, made with her prescriber. My job is to give her accurate information and to make sure the conversation happens; if she wants to stop, it should be a planned taper with monitoring, not an abrupt stop, and she should know what early warning signs to watch for.

Also ask the question she did not ask: why now? A request to "get it out of the milk" three weeks before returning to work often signals anticipatory anxiety about separation, supply and childcare. Ask about sleep, supports, and how she imagines the first week back. Refer to her maternity or mental health clinician if her mood is deteriorating, and document the discussion and the referral.